Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment.
- Autores: Borges JP, Dias SJ, Ferreira IM, Novo C, Soares PI
- Ano de Publicação: 2012
- Journal: Mini-Reviews in Medicinal Chemistry
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Doxorubicin+vs.+ladirubicin%3A+methods+for+improving+osteosarcoma+treatment
Osteosarcoma is the most common primary bone tumor in children and adolescents, with a 5-year disease free survival rate of 70%. Current chemotherapy regimens comprise a group of chemotherapeutic agents in which doxorubicin is included. However, tumor resistance to anthracyclines and cardiotoxicity are limiting factors for its usage.